Paper: Assessment of the realistic performance of a high payload dry powder inhaler for the delivery of biomolecules to the respiratory tract
Antonia Zapata del Baño is currently a Principal Scientist at Nanopharm Ltd, an Aptar Pharma Company (UK) in the New Modalities Pharmaceutical Development department.
She studied Biotechnology as Bachelor’s degree at University of Murcia (ES) in 2016, preparing a dissertation on the state of the art and different activity of long non-coding RNA.
In 2017, she collaborated as a Research Assistant at Oxford Brookes University (UK), where she worked on a project characterising functional properties of nicotinic acetylcholine receptors in Xenopus oocytes.
In 2019, she obtained a MSc in Biomolecules and Cell Dynamics at Autonomous University of Madrid (ES), working on a project focused on understanding the role of the membrane contact sites and lipid trafficking in autophagy.
She joined Nanopharm later that same year, covering different roles from Pharmaceutical Analyst to Senior Scientist and then to her current position as a Principal Scientist. During these three years, she acquired competences in respiratory and nasal drug delivery, focusing particularly on pressurised metered dose inhalers and dry powder inhalers in vitro characterization and, more recently, on the development of nasal sprays comprising antibodies and proteins against viral infections.
DDL 2022 is going to be her fourth participation in a conference dedicated to pulmonary and nasal drug delivery.